Fulton Bank N.A. Buys 19,852 Shares of Pfizer Inc. $PFE

Fulton Bank N.A. increased its position in shares of Pfizer Inc. (NYSE:PFE) by 24.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 99,760 shares of the biopharmaceutical company’s stock after purchasing an additional 19,852 shares during the period. Fulton Bank N.A.’s holdings in Pfizer were worth $2,418,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Bessemer Group Inc. raised its holdings in shares of Pfizer by 11.1% in the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock worth $3,358,000 after buying an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK grew its holdings in Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock worth $35,817,000 after acquiring an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp bought a new position in Pfizer in the 1st quarter worth approximately $8,283,000. Westbourne Investments Inc. acquired a new position in shares of Pfizer during the first quarter valued at $2,411,000. Finally, Bourne Lent Asset Management Inc. boosted its stake in shares of Pfizer by 90.8% in the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after purchasing an additional 18,200 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on PFE. Morgan Stanley upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Jefferies Financial Group raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st. Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Bank of America lifted their price target on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Berenberg Bank lowered their target price on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Thursday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.12.

Pfizer Stock Up 0.5%

Shares of NYSE PFE opened at $24.03 on Thursday. The company has a 50-day moving average price of $24.70 and a 200-day moving average price of $24.25. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The stock has a market capitalization of $136.62 billion, a P/E ratio of 12.78, a P/E/G ratio of 0.85 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same period last year, the business earned $0.60 EPS. The business’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer’s dividend payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.